TNFSF10 and neoplasm: The observations that TRAIL death receptors are frequently overexpressed in cancer and that TRAIL induces apoptosis in tumor cells and not normal healthy cells led to the development of TRAIL/TRAIL-R-based therapeutic drugs and their testing in clinical trials (Lemke et al., 2014; de Miguel et al., 2016).